These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 7577211)

  • 1. Prostate Cancer Intervention Versus Observation Trial: economic analysis in study design and conditions of uncertainty.
    Schwartz JS
    J Natl Cancer Inst Monogr; 1995; (19):73-5. PubMed ID: 7577211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
    McNaughton-Collins M; Walker-Corkery E; Barry MJ
    J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer.
    Wilt TJ; Brawer MK
    Semin Urol; 1995 May; 13(2):130-6. PubMed ID: 7638470
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT Planning Committee.
    Moon TD; Brawer MK; Wilt TJ
    J Natl Cancer Inst Monogr; 1995; (19):69-71. PubMed ID: 7577210
    [No Abstract]   [Full Text] [Related]  

  • 6. "Just Another Statistic".
    Machtay M; Glatstein E
    Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis, management and screening of early localised prostate cancer.
    Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
    Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methodological issues in studies of the treatment, diagnosis, and etiology of prostate cancer.
    Begg CB
    Semin Oncol; 1994 Oct; 21(5):569-79. PubMed ID: 7939748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
    Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
    Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prostate Cancer Intervention Versus Observation Trial (PIVOT).
    Wilt TJ; Brawer MK
    Oncology (Williston Park); 1997 Aug; 11(8):1133-9; discussion 1139-40, 1143. PubMed ID: 9268976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quantitative analysis of the costs and benefits of prostate cancer screening.
    Benoit RM; Grönberg H; Naslund MJ
    Prostate Cancer Prostatic Dis; 2001; 4(3):138-145. PubMed ID: 12497031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer.
    Wilt TJ; Brawer MK
    J Urol; 1994 Nov; 152(5 Pt 2):1910-4. PubMed ID: 7523736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. We need better randomized comparison trials of prostate cancer.
    Lee WR
    Cancer; 2010 Jan; 116(2):270-2. PubMed ID: 19924796
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of localized prostate cancer: an epidemiological perspective.
    Harwood RH
    Clin Oncol (R Coll Radiol); 1995; 7(3):151-9. PubMed ID: 7547516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Prostate Cancer Intervention Versus Observation Trial (PIVOT) in Perspective.
    Cheng JY
    J Clin Med Res; 2013 Aug; 5(4):266-8. PubMed ID: 23864914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching therapy in health economics trials: confronting the confusion.
    Torrance GW; Drummond MF; Walker V
    Med Decis Making; 2003; 23(4):335-40. PubMed ID: 12926583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.